TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32795330

Group type: EXPERIMENTAL
Intervention: Auxora
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 30
Study: 34616116

Group type: EXPERIMENTAL
Intervention: Selective percutaneous myofascial lengthening (SPML) procedure and 9-month functional strengthening physiotherapy programme
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 52
Study: 35254443

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 35974018

Group type: EXPERIMENTAL
Intervention: Nomogram model based on physical examination and laboratory tests
Number of subjects: 8861
Study: 33307235

Group type: EXPERIMENTAL
Intervention: 2.25% NaOCl with 17% EDTA and ECL (group 4)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ethanol based propolis (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Photoactivated disinfection (PAD) (group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ozone (group 3)
Number of subjects: 40
Study: 36073014

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (eicosapentaenoic acid and docosahexaenoic acid)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 35895381

Group type: EXPERIMENTAL
Intervention: Nivolumab (360 mg) + gemcitabine and cisplatin (days 1 and 8 every 3 weeks for 6 months) followed by nivolumab (240 mg every 2 weeks)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) + ipilimumab (1 mg/kg every 6 weeks)
Number of subjects: 75
Study: 32880227

Group type: EXPERIMENTAL
Intervention: Stabilization Training for Adolescent Refugees with Trauma Induced Disorders
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waiting control condition
Number of subjects: 46
Study: 35578360

Group type: EXPERIMENTAL
Intervention: Dalbavancin (two doses on days 1 and 8)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard intravenous antibiotic therapy (4–8 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 200
Study: 34892404

Group type: EXPERIMENTAL
Intervention: GREEN vPPG method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: POS vPPG method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICA vPPG method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CHROM vPPG method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Averages of the green color intensity
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isometric hand grip exercise and leg ischemia
Number of subjects: 10
Study: 32546180

Group type: EXPERIMENTAL
Intervention: SMS notification prior to sending questionnaires
Number of subjects: 1394

Group type: COMPARATOR
Intervention: No SMS notification
Number of subjects: 1394

Group type: EXPERIMENTAL
Intervention: £10 voucher sent with the invitation letter for the primary follow‐up visit at 24 months
Number of subjects: 1394

Group type: COMPARATOR
Intervention: £10 voucher given at the visit
Number of subjects: 1394
Study: 33982267

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 0.75% BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream 1.5% BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruxolitinib cream (any strength)
Number of subjects: 0
Study: 35332558

Group type: EXPERIMENTAL
Intervention: Inebilizumab 300 mg intravenous dose administered on Day 1 and Day 15 and every 6 months thereafter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33735712

Group type: EXPERIMENTAL
Intervention: Favipiravir (1.6 gr loading, 1.8 gr daily)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (800/200 mg daily)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 380

Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir
Number of subjects: 380
Study: 32040222

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 151
Study: 36377764

Group type: EXPERIMENTAL
Intervention: Targeted community health worker (CHW) intervention
Number of subjects: 243908

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 243908
Study: 36147433

Group type: EXPERIMENTAL
Intervention: Quadratus lumborum (QL) block
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transversus abdominis plane (TAP) block
Number of subjects: 80
Study: 35748451

Group type: EXPERIMENTAL
Intervention: Ozonoid olive oil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 30
Study: 34482574

Group type: EXPERIMENTAL
Intervention: Combination of omega-3 fatty acids (300 mg daily) and vitamin D3 (50,000 IU weekly)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation (300 mg daily)
Number of subjects: 146
Study: 32788052

Group type: EXPERIMENTAL
Intervention: Patients with ED (ED+ group)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Healthy individuals (ED- group)
Number of subjects: 123
Study: 34814899

Group type: EXPERIMENTAL
Intervention: Multi-level diabetes management intervention (including group education sessions on diabetes management, physical activity, and diet/nutrition)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Multi-level diabetes management intervention
Number of subjects: 886

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 886
Study: 32334551

Group type: EXPERIMENTAL
Intervention: 42.5 g of almonds per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: No almond consumption
Number of subjects: 0
Study: 33412515

Group type: EXPERIMENTAL
Intervention: Factually correct blog article
Number of subjects: 141

Group type: COMPARATOR
Intervention: Factually incorrect blog article
Number of subjects: 141
Study: 32057842

Group type: EXPERIMENTAL
Intervention: Low-calorie sweetener (LCS) sweetened fruit squash drinks
Number of subjects: 155

Group type: COMPARATOR
Intervention: Water
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Diet (LCS-sweetened) cola
Number of subjects: 155

Group type: COMPARATOR
Intervention: Carbonated water
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Sugar-containing cola
Number of subjects: 155
Study: 36124078

Group type: EXPERIMENTAL
Intervention: Wearing a surgical mask
Number of subjects: 35

Group type: COMPARATOR
Intervention: Not wearing a surgical mask
Number of subjects: 35
Study: 32108326

Group type: EXPERIMENTAL
Intervention: Three-field lymphadenectomy
Number of subjects: 400

Group type: COMPARATOR
Intervention: Two-field lymphadenectomy
Number of subjects: 400
Study: 35725950

Group type: EXPERIMENTAL
Intervention: Inferior Meatus Antrostomy (IMA) with basal mucosa electrocoagulation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Middle Meatus Antrostomy (MMA)
Number of subjects: 107
Study: 34153248

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus nerve block
Number of subjects: 24

Group type: COMPARATOR
Intervention: Regional anesthesia with local infiltration
Number of subjects: 24
Study: 35130836

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Eptinezumab (pooled)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Eptinezumab (≥75% MRR)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Eptinezumab (≥50-<75% MRR)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 1149
Study: 32400122

Group type: EXPERIMENTAL
Intervention: Antiplatelet/Anticoagulant therapy
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Lowest platelet quartile (platelet count <187)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Antiplatelet/Anticoagulant therapy in lowest platelet quartile
Number of subjects: 482

Group type: COMPARATOR
Intervention: Overall cohort
Number of subjects: 482
Study: 35616948

Group type: COMPARATOR
Intervention: Supine position RT (50 Gy in 25 fractions or hypofractionation of 42.5 Gy in 16 fractions)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Prone position RT (50 Gy in 25 fractions or hypofractionation of 42.5 Gy in 16 fractions)
Number of subjects: 357
Study: 34003456

Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted radical vaginal hysterectomy (LARVH)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Vaginally assisted laparoscopic or robotic radical hysterectomy (VALRRH)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesometrial resection (TMMR)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (gynecological clinics)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Control group (urogynaecological patients)
Number of subjects: 261
Study: 33725464

Group type: EXPERIMENTAL
Intervention: Greek yogurt
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% fat milk
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 40
Study: 33087047

Group type: EXPERIMENTAL
Intervention: IVIg (human) - four vials daily for 3 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: IVIg
Number of subjects: 59
Study: 33860928

Group type: EXPERIMENTAL
Intervention: Recommendations for modelling test-treatment pathways in economic evaluations of PM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-randomised controlled trial data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parameterisation of structural uncertainty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consideration of perspective and discounting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of premature survival data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of additional value elements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient and clinician compliance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Managed entry agreements
Number of subjects: 0
Study: 35654659

Group type: EXPERIMENTAL
Intervention: Avelumab plus Best Supportive Care (BSC)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC) alone
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Avelumab plus BSC
Number of subjects: 700
Study: 33210444

Group type: EXPERIMENTAL
Intervention: Salmeterol 400 μg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Salmeterol 200 μg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Salmeterol 200 μg for seven consecutive days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Combined salmeterol and α-hydroxysalmeterol urine threshold
Number of subjects: 11
Study: 32483079

Group type: COMPARATOR
Intervention: Normal attire (baseline)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Full PPE
Number of subjects: 108
Study: 33891194

Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2 on day one and eight of each 21-day cycle)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment of physician’s choice (TPC) including paclitaxel, docetaxel, nab-paclitaxel or vinorelbine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Treatment of physician’s choice (TPC)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 58
Study: 32880655

Group type: EXPERIMENTAL
Intervention: Early Adenotonsillectomy (AT)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Watchful waiting with supportive care
Number of subjects: 453
Study: 35446078

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Duluth Model
Number of subjects: 338
Study: 33849853

Group type: EXPERIMENTAL
Intervention: Footprints to Better Balance (FBB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 32857051

Group type: EXPERIMENTAL
Intervention: Curry solution (distilled water with curry powder containing turmeric)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coffee solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Red wine solution
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tea solution
Number of subjects: 100
Study: 34520728

Group type: EXPERIMENTAL
Intervention: SpeakOut intervention
Number of subjects: 520

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 520
Study: 33855883

Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding (THR) program for 6 weeks
Number of subjects: 20
Study: 35754198

Group type: EXPERIMENTAL
Intervention: collagen plug with cyano‐acrylate (CPC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: platelet rich fibrin (PRF) + sutures
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: palatal stent only (PS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: collagen plug + sutures (CPS)
Number of subjects: 72
Study: 33145841

Group type: EXPERIMENTAL
Intervention: TAS-303 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAS-303 6 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAS-303 (3 mg and 6 mg)
Number of subjects: 0
Study: 33870433

Group type: EXPERIMENTAL
Intervention: Weight gain (2.6‐6.4 kg/m2)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Weight gain (2.6‐6.4 kg/m2) in women
Number of subjects: 340

Group type: COMPARATOR
Intervention: Weight maintenance (± 0.5 kg/m2)
Number of subjects: 340
Study: 32163797

Group type: EXPERIMENTAL
Intervention: Web-based peer-support program 'Supporting a First-time Mother'
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36241388

Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty (ESG)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Lifestyle interventions (LS)
Number of subjects: 36
Study: 34320651

Group type: EXPERIMENTAL
Intervention: IM‐MS lymph node irradiation
Number of subjects: 4004

Group type: COMPARATOR
Intervention: No IM‐MS lymph node irradiation
Number of subjects: 4004
Study: 32164777

Group type: EXPERIMENTAL
Intervention: Combined educational and electronic reminder system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36307874

Group type: EXPERIMENTAL
Intervention: Active tibial nerve stimulation using the Geko™ device, self-administered at home twice per week for 30 minutes over 3 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 0
Study: 34529931

Group type: EXPERIMENTAL
Intervention: Daratumumab maintenance (16 mg/kg intravenously every 8 weeks for 2 years)
Number of subjects: 886

Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Daratumumab maintenance
Number of subjects: 886
Study: 32162946

Group type: EXPERIMENTAL
Intervention: Prekindergarten mathematics curriculum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonequivalent comparison group design (NECGD) combining local comparison group, pretest measure, and 19 covariates
Number of subjects: 0
Study: 35483979

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 1462

Group type: COMPARATOR
Intervention: Bempedoic acid (initiated after placebo)
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (130 weeks)
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Bempedoic acid (78 weeks)
Number of subjects: 1462
Study: 33564016

Group type: EXPERIMENTAL
Intervention: bevacizumab
Number of subjects: 132

Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 132
Study: 35105570

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg daily for 3 days before surgery and 0.5 mg daily for 5 days after surgery)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (same schedule as colchicine)
Number of subjects: 132
Study: 33689854

Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with carbogen (98% O2; 2% CO2) and nicotinamide (CON)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Radical radiation therapy alone (RT)
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with CON in patients with tumor necrosis
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with CON in patients with high hypoxia gene score
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Radical radiation therapy with CON in patients with basal molecular subtype
Number of subjects: 333
Study: 93092255

Group type: EXPERIMENTAL
Intervention: Wellferon (lymphoblastoid interferon-alpha)
Number of subjects: 801

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 801
Study: 35934281

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) with an eating window ≤10 h/day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Habitual prolonged eating window (HABIT) with an eating window ≥14 h/day
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 62
Study: 33559428

Group type: EXPERIMENTAL
Intervention: Silver needle heat conduction therapy + loxoprofen sodium patch (combination group)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Loxoprofen sodium patch (loxoprofen group)
Number of subjects: 92
Study: 32239291

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study: 32410059

Group type: EXPERIMENTAL
Intervention: Vereos SiPM PET
Number of subjects: 30

Group type: COMPARATOR
Intervention: D690 PMT PET
Number of subjects: 30
Study: 32449919

Group type: EXPERIMENTAL
Intervention: Impaired BP recovery (systolic)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Impaired BP recovery (diastolic)
Number of subjects: 55
Study: 34166030

Group type: EXPERIMENTAL
Intervention: Family Foundations Home Visiting (FFHV) - 11 in-home sessions focusing on parental cooperation, collaboration, and conflict management
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Family Foundations Home Visiting (FFHV)
Number of subjects: 150
Study: 33559851

Group type: EXPERIMENTAL
Intervention: OL-HDFcit (dialysate containing one mmol of citric acid)
Number of subjects: 47

Group type: COMPARATOR
Intervention: OL-HDFst (standard dialysate containing three mmol of acetic acid)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: OL-HDFcit
Number of subjects: 47

Group type: COMPARATOR
Intervention: OL-HDFst
Number of subjects: 47
Study: 32473817

Group type: EXPERIMENTAL
Intervention: Treatment centers in Upper Egypt
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All treatment centers
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Monfiya Governorate (Lower Egypt) and Aswan (Upper Egypt)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Kalyoubia (Lower Egypt) and Sohag Governorate (Upper Egypt)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall performance of treatment centers
Number of subjects: 24
Study: 36457343

Group type: EXPERIMENTAL
Intervention: WBV exercise with surgical mask
Number of subjects: 47

Group type: COMPARATOR
Intervention: WBV exercise without surgical mask
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Different vibration frequency protocols (A, B, C)
Number of subjects: 47
Study: 33452201

Group type: EXPERIMENTAL
Intervention: 4-week telehealth CBT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 8-week telehealth CBT
Number of subjects: 80

Group type: COMPARATOR
Intervention: no-CBT
Number of subjects: 80
Study: 32441302

Group type: EXPERIMENTAL
Intervention: Costoclavicular approach (CC) with modified double-injection technique
Number of subjects: 112

Group type: COMPARATOR
Intervention: Supraclavicular approach (SC) with modified double-injection technique
Number of subjects: 112
Study: 36316075

Group type: EXPERIMENTAL
Intervention: Minimally invasive total gastrectomy (MIG)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Open total gastrectomy (OG)
Number of subjects: 160
Study: 36451509

Group type: EXPERIMENTAL
Intervention: Biodegradable microneedle acupuncture (BMA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional intradermal acupuncture
Number of subjects: 30
Study: 33624081

Group type: EXPERIMENTAL
Intervention: Boosted protease inhibitor (bPI) plus lamivudine dual therapy
Number of subjects: 265

Group type: COMPARATOR
Intervention: Boosted protease inhibitor (bPI) monotherapy
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Dual therapy (bPI + lamivudine)
Number of subjects: 265
Study: 32054059

Group type: EXPERIMENTAL
Intervention: Jump-in intervention
Number of subjects: 0
Study: 34027782

Group type: EXPERIMENTAL
Intervention: Foley’s‐misoprostol (25 µg vaginal misoprostol tablet)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Foley’s‐dinoprostone (0.5 mg intracervical dinoprostone gel)
Number of subjects: 150
Study: 34658941

Group type: EXPERIMENTAL
Intervention: Cysteine-rich whey protein (CRWP) 0.5 g/kg for children <20 kg or 10 g for those >20 kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (rice protein)
Number of subjects: 46
Study: 32679021

Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine plus JPJDF (Flu-F-treated group, n = 69)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Fluoropyrimidine (Flu-treated group, n = 68)
Number of subjects: 137
Study: 35763390

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1000 IU/day
Number of subjects: 635
Study: 34200027

Group type: EXPERIMENTAL
Intervention: Healthy Low-Carbohydrate (HLC) diet
Number of subjects: 609

Group type: COMPARATOR
Intervention: Healthy Low-Fat (HLF) diet
Number of subjects: 609
Study: 34989325

Group type: EXPERIMENTAL
Intervention: RADoralex®
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sodium bicarbonate solution
Number of subjects: 90
Study: 32587272

Group type: EXPERIMENTAL
Intervention: Cervical decompression surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study: 33196779

Group type: EXPERIMENTAL
Intervention: Self-management intervention (n = 69)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Education intervention (n = 85)
Number of subjects: 154
Study: 37658343

Group type: EXPERIMENTAL
Intervention: MOHMQuit intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0